Alnylam Pharma (ALNY) Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 224.03 -3.25 (1.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $227.28 | 52 Week High | $109.10 | |||
| Open | $227.28 | 52 Week Low | $31.38 | |||
| Day High | $229.39 | P/E | N/A | |||
| Day Low | $222.00 | EPS | $-1.45 | |||
| Volume | 1,055,960 | |||||
